Afinitor
everolimus
- Strength
- 7.5 mg/1
- Form
- Tablet
- Class
- Kinase Inhibitor; mTOR Inhibitor Immuno…
Novartis Pharmaceuticals Corporation
Listed by Hikma Pharmaceuticals USA Inc.
| Dosage form | Tablet |
|---|---|
| Route | Oral |
| Drug class | Kinase Inhibitor; mTOR Inhibitor Immunosuppressant |
| Approval route | ANDA — approved generic |
| NDC code | 0054-0470 |
| FDA application | ANDA206133 |
| RxNorm concept | 977427 |
| Package sizes listed | 1 |
| Marketed since | March 2020 |
Same active ingredient, different manufacturer, strength or form. Products matching on both ingredient and strength are usually interchangeable — but confirm before switching, especially with modified-release forms.
everolimus
Novartis Pharmaceuticals Corporation
everolimus
Novartis Pharmaceuticals Corporation
everolimus
Novartis Pharmaceuticals Corporation
everolimus
Novartis Pharmaceuticals Corporation
everolimus
Novartis Pharmaceuticals Corporation
everolimus
Novartis Pharmaceuticals Corporation
everolimus
Novartis Pharmaceuticals Corporation
Aurobindo Pharma Limited
Information only, not medical advice. Nothing on this page indicates that a medication is safe or suitable for you. Speak to a prescriber or pharmacist before starting, stopping or switching any medicine.
Please don't share card details in chat.